Quick Take
Metacrine (MTCR) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatment candidates for NASH conditions.
MTCR is entering Phase 2 trials and will have significant capital to pursue its treatments for a large and growing disease.
For life science investors with an 18 - 24-month hold time frame, the IPO may be worth considering.
Company & Technology
San Diego, California-based Metacrine was founded to research treatments for NASH (NonAlcoholic SteatoHepatitis), which is a